Palisade Bio, Inc. (PALI) |
|
2.24 0.02 (0.9%)
|
01-27 16:00 |
|
Open: |
2.17 |
Pre. Close: |
2.22 |
|
High:
|
2.245 |
Low:
|
2.11 |
|
Volume:
|
368,434 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:46:56 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.94 One year: 9.97 |
| Support: |
Support1: 1.74 Support2: 1.44 |
| Resistance: |
Resistance1: 5.94 Resistance2: 8.53 |
| Pivot: |
2.54  |
| Moving Average: |
MA(5): 2.33 MA(20): 2.88 
MA(100): 4.17 MA(250): 20.63 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 6.4 %D(3): 5.4 |
| RSI: |
RSI(14): 42.1 |
| 52-week: |
High: 76.5 Low: 0.44 |
| Average Vol(K): |
3-Month: 3,497 (K) 10-Days: 455 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PALI ] has closed above bottom band by 11.8%. Bollinger Bands are 68.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.25 - 2.26 |
2.26 - 2.27 |
|
Low:
|
2.08 - 2.1 |
2.1 - 2.11 |
|
Close:
|
2.22 - 2.24 |
2.24 - 2.26 |
|
Company Description |
|
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California. |
Headline News |
Sat, 28 Jan 2023
Pali Medical College gets Centre’s nod for PG courses - Times of India
Sat, 28 Jan 2023
Palisade Bio Inc. (NASDAQ:PALI) Rises 59.40% In 2023; Is It Still ... - Marketing Sentinel
Fri, 27 Jan 2023
Here is why Palisade Bio Inc. (PALI) stock volatility recorded over ... - Invest Chronicle
Wed, 25 Jan 2023
Hacked road sign along Pali Highway tied to deadly protests in GA - Hawaii News Now
Mon, 23 Jan 2023
Premarket Mover: Palisade Bio Inc (PALI) Up 1.68% - InvestorsObserver
Tue, 17 Jan 2023
Palisade Bio Inc (PALI) Down 2.62% in Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
11.4 (%) |
|
% Held by Institutions
|
11 (%) |
|
Shares Short
|
98 (K) |
|
Shares Short P.Month
|
3 (K) |
Stock Financials |
|
EPS
|
11.44 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
8.06 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-58 |
|
Return on Equity (ttm)
|
-115.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-7.48 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-13 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
0.19 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.27 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-07-17 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
